193 related articles for article (PubMed ID: 29296959)
1. Somatic mutations in children with
Fisher KE; Hsu AP; Williams CL; Sayeed H; Merritt BY; Elghetany MT; Holland SM; Bertuch AA; Gramatges MM
Blood Adv; 2017 Feb; 1(7):443-448. PubMed ID: 29296959
[TBL] [Abstract][Full Text] [Related]
2. [Clinical and molecular characteristics of GATA2 related pediatric primary myelodysplastic syndrome].
An WB; Liu C; Wan Y; Chen XY; Guo Y; Chen XJ; Yang WY; Chen YM; Zhang YC; Zhu XF
Zhonghua Xue Ye Xue Za Zhi; 2019 Jun; 40(6):477-483. PubMed ID: 31340620
[No Abstract] [Full Text] [Related]
3. Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents.
Wlodarski MW; Hirabayashi S; Pastor V; Starý J; Hasle H; Masetti R; Dworzak M; Schmugge M; van den Heuvel-Eibrink M; Ussowicz M; De Moerloose B; Catala A; Smith OP; Sedlacek P; Lankester AC; Zecca M; Bordon V; Matthes-Martin S; Abrahamsson J; Kühl JS; Sykora KW; Albert MH; Przychodzien B; Maciejewski JP; Schwarz S; Göhring G; Schlegelberger B; Cseh A; Noellke P; Yoshimi A; Locatelli F; Baumann I; Strahm B; Niemeyer CM;
Blood; 2016 Mar; 127(11):1387-97; quiz 1518. PubMed ID: 26702063
[TBL] [Abstract][Full Text] [Related]
4. Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia.
Churpek JE; Pyrtel K; Kanchi KL; Shao J; Koboldt D; Miller CA; Shen D; Fulton R; O'Laughlin M; Fronick C; Pusic I; Uy GL; Braunstein EM; Levis M; Ross J; Elliott K; Heath S; Jiang A; Westervelt P; DiPersio JF; Link DC; Walter MJ; Welch J; Wilson R; Ley TJ; Godley LA; Graubert TA
Blood; 2015 Nov; 126(22):2484-90. PubMed ID: 26492932
[TBL] [Abstract][Full Text] [Related]
5. Heritable GATA2 mutations associated with familial AML-MDS: a case report and review of literature.
Gao J; Gentzler RD; Timms AE; Horwitz MS; Frankfurt O; Altman JK; Peterson LC
J Hematol Oncol; 2014 Apr; 7():36. PubMed ID: 24754962
[TBL] [Abstract][Full Text] [Related]
6. ASXL1 and STAG2 are common mutations in GATA2 deficiency patients with bone marrow disease and myelodysplastic syndrome.
West RR; Calvo KR; Embree LJ; Wang W; Tuschong LM; Bauer TR; Tillo D; Lack J; Droll S; Hsu AP; Holland SM; Hickstein DD
Blood Adv; 2022 Feb; 6(3):793-807. PubMed ID: 34529785
[TBL] [Abstract][Full Text] [Related]
7. Somatic genetic alterations predict hematological progression in GATA2 deficiency.
Largeaud L; Collin M; Monselet N; Vergez F; Fregona V; Larcher L; Hirsch P; Duployez N; Bidet A; Luquet I; Bustamante J; Dufrechou S; Prade N; Nolla M; Hamelle C; Tavitian S; Habib C; Meynier M; Bellanne-Chantelot C; Donadieu J; De Fontbrune FS; Fieschi C; Ferster A; Delhommeau F; Delabesse E; Pasquet M
Haematologica; 2023 Jun; 108(6):1515-1529. PubMed ID: 36727400
[TBL] [Abstract][Full Text] [Related]
8. Germ-line GATA2 p.THR354MET mutation in familial myelodysplastic syndrome with acquired monosomy 7 and ASXL1 mutation demonstrating rapid onset and poor survival.
Bödör C; Renneville A; Smith M; Charazac A; Iqbal S; Etancelin P; Cavenagh J; Barnett MJ; Kramarzová K; Krishnan B; Matolcsy A; Preudhomme C; Fitzgibbon J; Owen C
Haematologica; 2012 Jun; 97(6):890-4. PubMed ID: 22271902
[TBL] [Abstract][Full Text] [Related]
9. Loss-of-function germline GATA2 mutations in patients with MDS/AML or MonoMAC syndrome and primary lymphedema reveal a key role for GATA2 in the lymphatic vasculature.
Kazenwadel J; Secker GA; Liu YJ; Rosenfeld JA; Wildin RS; Cuellar-Rodriguez J; Hsu AP; Dyack S; Fernandez CV; Chong CE; Babic M; Bardy PG; Shimamura A; Zhang MY; Walsh T; Holland SM; Hickstein DD; Horwitz MS; Hahn CN; Scott HS; Harvey NL
Blood; 2012 Feb; 119(5):1283-91. PubMed ID: 22147895
[TBL] [Abstract][Full Text] [Related]
10. Successful umbilical cord blood hematopoietic stem cell transplantation in pediatric patients with MDS/AML associated with underlying GATA2 mutations: two case reports and review of literature.
Mallhi K; Dix DB; Niederhoffer KY; Armstrong L; Rozmus J
Pediatr Transplant; 2016 Nov; 20(7):1004-1007. PubMed ID: 27416790
[TBL] [Abstract][Full Text] [Related]
11. GATA2 deficiency and related myeloid neoplasms.
Wlodarski MW; Collin M; Horwitz MS
Semin Hematol; 2017 Apr; 54(2):81-86. PubMed ID: 28637621
[TBL] [Abstract][Full Text] [Related]
12. High penetrance of myeloid neoplasia with diverse clinical and cytogenetic features in three siblings with a familial GATA2 deficiency.
Ellingford JM; Telford N; Urquhart J; Will AM; Bonney D; Adams B; Dixon R; Kerr B; Black GC; Wynn RF; Meyer S
Cancer Genet; 2021 Aug; 256-257():77-80. PubMed ID: 33957466
[TBL] [Abstract][Full Text] [Related]
13. GATA2 Deficiency: Predisposition to Myeloid Malignancy and Hematopoietic Cell Transplantation.
Rajput RV; Arnold DE
Curr Hematol Malig Rep; 2023 Aug; 18(4):89-97. PubMed ID: 37247092
[TBL] [Abstract][Full Text] [Related]
14. [Predisposition and progression of myelodysplastic syndromes].
Makishima H
Rinsho Ketsueki; 2021; 62(4):278-288. PubMed ID: 33967153
[TBL] [Abstract][Full Text] [Related]
15. Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progression.
Hou HA; Kuo YY; Tang JL; Chou WC; Yao M; Lai YJ; Lin CC; Chen CY; Liu CY; Tseng MH; Huang CF; Chiang YC; Lee FY; Liu MC; Liu CW; Huang SY; Ko BS; Wu SJ; Tsay W; Chen YC; Tien HF
Am J Hematol; 2014 Feb; 89(2):181-6. PubMed ID: 24127063
[TBL] [Abstract][Full Text] [Related]
16. MDS-associated mutations in germline GATA2 mutated patients with hematologic manifestations.
McReynolds LJ; Yang Y; Yuen Wong H; Tang J; Zhang Y; Mulé MP; Daub J; Palmer C; Foruraghi L; Liu Q; Zhu J; Wang W; West RR; Yohe ME; Hsu AP; Hickstein DD; Townsley DM; Holland SM; Calvo KR; Hourigan CS
Leuk Res; 2019 Jan; 76():70-75. PubMed ID: 30578959
[TBL] [Abstract][Full Text] [Related]
17. GATA2 deficiency and MDS/AML: Experimental strategies for disease modelling and future therapeutic prospects.
Kotmayer L; Romero-Moya D; Marin-Bejar O; Kozyra E; Català A; Bigas A; Wlodarski MW; Bödör C; Giorgetti A
Br J Haematol; 2022 Nov; 199(4):482-495. PubMed ID: 35753998
[TBL] [Abstract][Full Text] [Related]
18. Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation.
Della Porta MG; Gallì A; Bacigalupo A; Zibellini S; Bernardi M; Rizzo E; Allione B; van Lint MT; Pioltelli P; Marenco P; Bosi A; Voso MT; Sica S; Cuzzola M; Angelucci E; Rossi M; Ubezio M; Malovini A; Limongelli I; Ferretti VV; Spinelli O; Tresoldi C; Pozzi S; Luchetti S; Pezzetti L; Catricalà S; Milanesi C; Riva A; Bruno B; Ciceri F; Bonifazi F; Bellazzi R; Papaemmanuil E; Santoro A; Alessandrino EP; Rambaldi A; Cazzola M
J Clin Oncol; 2016 Oct; 34(30):3627-3637. PubMed ID: 27601546
[TBL] [Abstract][Full Text] [Related]
19. Young woman with mild bone marrow dysplasia, GATA2 and ASXL1 mutation treated with allogeneic hematopoietic stem cell transplantation.
Lübking A; Vosberg S; Konstandin NP; Dufour A; Graf A; Krebs S; Blum H; Weber A; Lenhoff S; Ehinger M; Spiekermann K; Greif PA; Cammenga J
Leuk Res Rep; 2015; 4(2):72-5. PubMed ID: 26716079
[TBL] [Abstract][Full Text] [Related]
20. Implications of mutational spectrum in myelodysplastic syndromes based on targeted next-generation sequencing.
Xu Y; Li Y; Xu Q; Chen Y; Lv N; Jing Y; Dou L; Bo J; Hou G; Guo J; Wang X; Wang L; Li Y; Chen C; Yu L
Oncotarget; 2017 Oct; 8(47):82475-82490. PubMed ID: 29137279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
